410 related articles for article (PubMed ID: 26954019)
1. Drug Repositioning for Cancer Therapy Based on Large-Scale Drug-Induced Transcriptional Signatures.
Lee H; Kang S; Kim W
PLoS One; 2016; 11(3):e0150460. PubMed ID: 26954019
[TBL] [Abstract][Full Text] [Related]
2. Accurate Drug Repositioning through Non-tissue-Specific Core Signatures from Cancer Transcriptomes.
Xu C; Ai D; Shi D; Suo S; Chen X; Yan Y; Cao Y; Zhang R; Sun N; Chen W; McDermott J; Zhang S; Zeng Y; Han JJ
Cell Rep; 2018 Oct; 25(2):523-535.e5. PubMed ID: 30304690
[TBL] [Abstract][Full Text] [Related]
3. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
Chen B; Wei W; Ma L; Yang B; Gill RM; Chua MS; Butte AJ; So S
Gastroenterology; 2017 Jun; 152(8):2022-2036. PubMed ID: 28284560
[TBL] [Abstract][Full Text] [Related]
4. Integrating LINCS Data to Evaluate Cancer Transcriptome Modifying Potential of Small-molecule Compounds for Drug Repositioning.
Zhao Y; Liu Y; Bai H
Comb Chem High Throughput Screen; 2021; 24(9):1340-1350. PubMed ID: 33109034
[TBL] [Abstract][Full Text] [Related]
5. Repositioning FDA-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon Cancer Epigenome.
Raynal NJ; Da Costa EM; Lee JT; Gharibyan V; Ahmed S; Zhang H; Sato T; Malouf GG; Issa JJ
Mol Cancer Ther; 2017 Feb; 16(2):397-407. PubMed ID: 27980103
[TBL] [Abstract][Full Text] [Related]
6. Prediction of synergistic anti-cancer drug combinations based on drug target network and drug induced gene expression profiles.
Li X; Xu Y; Cui H; Huang T; Wang D; Lian B; Li W; Qin G; Chen L; Xie L
Artif Intell Med; 2017 Nov; 83():35-43. PubMed ID: 28583437
[TBL] [Abstract][Full Text] [Related]
7. Conservation of immune gene signatures in solid tumors and prognostic implications.
Chifman J; Pullikuth A; Chou JW; Bedognetti D; Miller LD
BMC Cancer; 2016 Nov; 16(1):911. PubMed ID: 27871313
[TBL] [Abstract][Full Text] [Related]
8. Signature reversion of three disease-associated gene signatures prioritizes cancer drug repurposing candidates.
Fisher JL; Wilk EJ; Oza VH; Gary SE; Howton TC; Flanary VL; Clark AD; Hjelmeland AB; Lasseigne BN
FEBS Open Bio; 2024 May; 14(5):803-830. PubMed ID: 38531616
[TBL] [Abstract][Full Text] [Related]
9. Computational Drug Repositioning for Gastric Cancer using Reversal Gene Expression Profiles.
Kim IW; Jang H; Kim JH; Kim MG; Kim S; Oh JM
Sci Rep; 2019 Feb; 9(1):2660. PubMed ID: 30804389
[TBL] [Abstract][Full Text] [Related]
10. Diverse gene expression patterns in response to anticancer drugs between human and mouse cell lines revealed by a comparative transcriptomic analysis.
Guo Y; Liang Z; Hou X; Zhang Z
Mol Med Rep; 2017 Oct; 16(4):4469-4474. PubMed ID: 28791417
[TBL] [Abstract][Full Text] [Related]
11. An in silico screen links gene expression signatures to drug response in glioblastoma stem cells.
Riddick G; Song H; Holbeck SL; Kopp W; Walling J; Ahn S; Zhang W; Fine HA
Pharmacogenomics J; 2015 Aug; 15(4):347-53. PubMed ID: 25446780
[TBL] [Abstract][Full Text] [Related]
12. Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset.
Seashore-Ludlow B; Rees MG; Cheah JH; Cokol M; Price EV; Coletti ME; Jones V; Bodycombe NE; Soule CK; Gould J; Alexander B; Li A; Montgomery P; Wawer MJ; Kuru N; Kotz JD; Hon CS; Munoz B; Liefeld T; Dančík V; Bittker JA; Palmer M; Bradner JE; Shamji AF; Clemons PA; Schreiber SL
Cancer Discov; 2015 Nov; 5(11):1210-23. PubMed ID: 26482930
[TBL] [Abstract][Full Text] [Related]
13. DeSigN: connecting gene expression with therapeutics for drug repurposing and development.
Lee BK; Tiong KH; Chang JK; Liew CS; Abdul Rahman ZA; Tan AC; Khang TF; Cheong SC
BMC Genomics; 2017 Jan; 18(Suppl 1):934. PubMed ID: 28198666
[TBL] [Abstract][Full Text] [Related]
14. Drug and disease signature integration identifies synergistic combinations in glioblastoma.
Stathias V; Jermakowicz AM; Maloof ME; Forlin M; Walters W; Suter RK; Durante MA; Williams SL; Harbour JW; Volmar CH; Lyons NJ; Wahlestedt C; Graham RM; Ivan ME; Komotar RJ; Sarkaria JN; Subramanian A; Golub TR; Schürer SC; Ayad NG
Nat Commun; 2018 Dec; 9(1):5315. PubMed ID: 30552330
[TBL] [Abstract][Full Text] [Related]
15. Identifying Gene Signatures for Cancer Drug Repositioning Based on Sample Clustering.
Wang F; Ding Y; Lei X; Liao B; Wu FX
IEEE/ACM Trans Comput Biol Bioinform; 2022; 19(2):953-965. PubMed ID: 32845842
[TBL] [Abstract][Full Text] [Related]
16. Expression Profiles of the Individual Genes Corresponding to the Genes Generated by Cytotoxicity Experiments with Bortezomib in Multiple Myeloma.
Ghasemi M; Alpsoy S; Türk S; Malkan ÜY; Atakan Ş; Haznedaroğlu İC; Güneş G; Gündüz M; Yılmaz B; Etgül S; Aydın S; Aslan T; Sayınalp N; Aksu S; Demiroğlu H; Özcebe OI; Büyükaşık Y; Göker H
Turk J Haematol; 2016 Dec; 33(4):286-292. PubMed ID: 27095044
[TBL] [Abstract][Full Text] [Related]
17. Improved anticancer drug response prediction in cell lines using matrix factorization with similarity regularization.
Wang L; Li X; Zhang L; Gao Q
BMC Cancer; 2017 Aug; 17(1):513. PubMed ID: 28768489
[TBL] [Abstract][Full Text] [Related]
18. Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells.
Gautam P; Karhinen L; Szwajda A; Jha SK; Yadav B; Aittokallio T; Wennerberg K
Mol Cancer; 2016 May; 15(1):34. PubMed ID: 27165605
[TBL] [Abstract][Full Text] [Related]
19. Statistically controlled identification of differentially expressed genes in one-to-one cell line comparisons of the CMAP database for drug repositioning.
He J; Yan H; Cai H; Li X; Guan Q; Zheng W; Chen R; Liu H; Song K; Guo Z; Wang X
J Transl Med; 2017 Sep; 15(1):198. PubMed ID: 28962576
[TBL] [Abstract][Full Text] [Related]
20. New drug candidates for treatment of atypical meningiomas: An integrated approach using gene expression signatures for drug repurposing.
Zador Z; King AT; Geifman N
PLoS One; 2018; 13(3):e0194701. PubMed ID: 29558515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
